Abstract
In vivo angiogenesis assays provide more physiologically relevant information about tumor vascularization than in vitro studies because they take the complex interactions among cancer cells, endothelial cells, mural cells, and tumor stroma into consideration. Traditional microscopic assessment of vascular density conducted by immunostaining of tissue sections or by lectin angiogram visualization of tumor vessels is invasive and requires the sacrifice of tumor-bearing animals. Therefore, it prohibits longitudinal time-course observation in a single animal and requires a large number of animals at each time point to derive statistically-meaningful observations. Additionally, heterogenous behavior among different tumors will inevitably introduce individual biological variance that may obscure reliable interpretation of the results. While various artificial in vivo angiogenesis assays, such as the Matrigel implant assay, chick chorioallatoic membrane assay, and dorsal skin fold chamber assay have been developed and employed to more directly observe the progression of physiological angiogenesis, they can not appropriately assess tumor angiogenic progression or tumor vascular regression in response to therapeutic intervention. Here, we describe a noninvasive method and a detailed protocol that we have developed and optimized using the Olympus OV-100 in vivo imaging system for real-time high-resolution visualization and assessment of tumor angiogenesis and vascular response to anticancer therapies in live animals. We show that using this approach, tumor vessels can be monitored longitudinally through the whole vasculogenesis and angiogenesis process in the same mouse. Further, morphologic changes of the same vessel prior to and after drug treatments can be captured with microscopic high resolution. Moreover, the multichannel co-imaging capability of the OV-100 allows us to analyze and compare tumor vessel permeability before and after antiangiogenesis therapy by employing a near-infrared blood pool reagent, or by visualizing improved cytotoxic drug delivery upon tumor vessel normalization by using a fluorophore tagged drug. This noninvasive method can be readily applied to orthotopically transplanted breast cancer models as well as to subcutaneously-transplanted tumor models.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan, D.and Weinberg R. A. (2000) The hallmarks of cancer. Cell 100, 57–70.
Naumov, G. N., Akslen, L. A., and Folkman, J. (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779–1787.
Bergers, G. and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401–410.
Burri, P. H. (2004) Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn. 231, 474–88. doi:10.1002/dvdy.20184.
Fukumura, D. and Jain, R. K. (2008) Imaging angiogenesis and the microenvironment. APMIS 116, 695–715.
Jain, R. K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62.
Staton, C. A., Stribbling, S. M., Tazzyman, S., Hughes, R., Brown, N. J., and Lewis, C. E. (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 85, 233–248.
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309.
Grothey, A. and Galanis, E. (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 9, 507–518.
Kerbel, R. and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727–739.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844.
Rowinsky, E. K. (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 16, 564–575
Noh, W. C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., et al. (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 10, 1013–1023.
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., et al. (2006) Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 159–170.
Zhang, Q., Bindokas, V.P., Shen, J., Fan, H., Hoffman, R.M., Xing, H.R. (2011) Time course imaging of therapeutic functional tumor vascular normalization by anti-angiogenic agents. Mol. Cancer Ther. 10, 1173–1184.
Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., et al. (2003) Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat. Med. 9, 1266–1268.
Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809–813.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
Xing, H.R., Zhang, Q. (2012). Real-Time Visualization and Characterization of Tumor Angiogenesis and Vascular Response to Anticancer Therapies. In: Hoffman, R. (eds) In Vivo Cellular Imaging Using Fluorescent Proteins. Methods in Molecular Biology, vol 872. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-797-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-797-2_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-796-5
Online ISBN: 978-1-61779-797-2
eBook Packages: Springer Protocols